-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
July 27, 2020 // A Brazilian man infected with AIDS has not developed any symptoms of the disease for more than a year after undergoing a high-intensity experimental drug therapy designed to remove latent virus esfound in his body.
picture source: Federica Narancio/Zoom University researcher Monica Gandhi said: 'This is an exciting study, but it's only a preliminary study, and it's only happening in one person, and it's not successful in four other people who received the same treatment; researcher Steven Deeks says it's not a cure, it's just an interesting case that deserves more research; at an AIDS conference, researchers Describing the case, the researchers also revealed an important development in injecting an experimental drug every two months that helps prevent uninfected gay men from contracting HIV from being infected with HIV, and that thousands of people are now taking Truvada to prevent HIV infection, a drug that provides a new option for individuals as a temporary vaccine.
If the Brazilian man's case is confirmed, it could be the first time HIV has been eliminated in adults without a bone marrow or stem cell transplant, and the researchers want to know if the patient's disease remission will continue and whether more tests will be performed on the combination of drugs he receives.
HIV cure may be the result many patients want, the 35-year-old told The Associated Press, speaking on condition of anonymity, this is the second gift of life and the second chance to survive.
it's very difficult to clean up HIV because it builds an early viral "store" in blood cells and sleeps, and can't be attacked by drugs or the immune system, using drugs to control HIV infection, but once the patient stops taking the drug, dormant HIV is reactivated and the disease relapses; researcher Ricardo Diaz says we've done a study to test whether a powerful new combination of drugs can clear the virus reservoir. Trying to wake up the virus and boost the body's immunity until it is eliminated, the Brazilian man has been taking a standard combination of three drugs to suppress the progression of the virus, and in 2019 researchers added two drugs to previous treatments, Dolutegravir and Malawiroc, a vitamin B3 that helps expose the latent virus.
nearly a year later, patients re-used the standard three drugs for more than two years, then stopped taking all of them in March 2019, and since then researchers have been unable to detect the presence of the virus in the patient's blood and tissue samples, and researcher Diaz says we can't search the body, but the strongest evidence is that we can't find the cells that the patient's body is infected with.
researchers found that the man had almost no HIV antibodies in his body, which is a special substance produced by the body's immune system when it comes to fighting HIV.
But the treatment doesn't seem to have worked in four other people, and now researchers are preparing a new study of 60 other patients who want to know whether HIV will actually rebound in patients.
followed a separate study of nearly 4,600 people from North America, South America, Asia and Africa, testing the effectiveness of the experimental drug cabotegravir and daily use of Truvada in fighting HIV infection; At the time, it seemed that cabotegravir was as effective as the Truvada pill, but the final results showed that the injection of cabotegravir worked better, with only 13 new infections in the injection group, compared with 39 in the Truvada group.
people take a pill every day to stay safe, but it's probably amazing that you don't have to do anything within two months of a single injection.
the results could revolutionise HIV prevention around the world and provide a new treatment option for those who don't want to take it every day; ViiV said it will seek U.S. approval for cabotegravir, but the price of the treatment is not determined, and Truvada costs patients $1,600-$1,800 a month, but the patient's out-of-pocket costs depend on insurance and other factors, and even if these drugs are used, people will still be warned to use condoms to prevent other sexually transmitted diseases from spreading.
() References: Doctors say treatment treatment may hasrid man for HIV.